Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes

Trial Profile

Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin aspart (Primary) ; Insulin degludec (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms onset8
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 01 Jun 2019 Post hoc analysis of Onset 1 and Onset 8 trial published in the Diabetes Therapy.
    • 05 Oct 2018 Results of post hoc analysis of onset 8 study assessing the impact of dose adjustment methodology (DAM) in relation to the efficacy and safety of mealtime faster aspart in T1D. presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
    • 30 Aug 2018 Primary endpoint has been met. (Change from baseline in HbA1c after 26 weeks of treatment) as per results published in the European Clinical Trials Database Trial Registry
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top